Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical ...

"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

This move represented a sharp increase in price on volume nearly 3x the average daily trading volume, indicating robust ...

Edgewise's EDG-7500 showed clinical activity and a favorable safety profile in Phase 2 trial for hypertrophic cardiomyopathy.

Scientists develop new blood test to identify individuals at high risk of developing hypertrophic cardiomyopathy, most common ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA ...

Edgewise Therapeutics (EWTX) stock rises as the company updates mid-stage trial results for EDG-7500, its test drug for ...

Hypertrophic cardiomyopathy (HCM) is an underdiagnosed genetic heart condition. Raising awareness through advocacy can help increase the rates of diagnosis and proper management. HCM is when the left ...

Future Cardiol. 2013;9(5):697-709. It is extremely important to detect the presence and severity of LVOT obstruction from physical examination, as well as 2D and Doppler echocardiography. The LVOT ...

Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...